These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 9532515)

  • 1. Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system.
    Hollenberg NK
    J Hypertens Suppl; 1997 Dec; 15(7):S7-13. PubMed ID: 9532515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
    Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
    Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Zanella MT; Ribeiro AB
    Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
    Rodby RA; Rohde RD; Clarke WR; Hunsicker LG; Anzalone DA; Atkins RC; Ritz E; Lewis EJ
    Nephrol Dial Transplant; 2000 Apr; 15(4):487-97. PubMed ID: 10727543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
    Burnier M; Zanchi A
    J Hypertens; 2006 Jan; 24(1):11-25. PubMed ID: 16331093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.
    Eberhard R; Dikow R
    Ann Med; 2002; 34(7-8):507-13. PubMed ID: 12553490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
    Ruilope LM
    Am J Hypertens; 1997 Dec; 10(12 Pt 2):325S-331S. PubMed ID: 9438777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing antihypertensive therapy in patients with diabetic nephropathy.
    Ritz E; Rychlík I; Miltenberger-Miltenyi G
    J Hypertens Suppl; 1998 Sep; 16(7):S17-22. PubMed ID: 9855027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin receptor blockers in diabetic nephropathy.
    Price DA; Hollenberg NK
    Curr Diab Rep; 2001 Dec; 1(3):267-74. PubMed ID: 12643209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.
    Matos JP; de Lourdes Rodrigues M; Ismerim VL; Boasquevisque EM; Genelhu V; Francischetti EA
    Clin Nephrol; 2005 Sep; 64(3):180-9. PubMed ID: 16175942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of irbesartan in the management of hypertension.
    Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
    Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy.
    García-Donaire JA; Segura J; Ruilope LM
    Expert Opin Pharmacother; 2005 Aug; 6(9):1587-96. PubMed ID: 16086646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study of the month. Nephroprotective role of angiotensin II receptor antagonists in type 2 diabetes: results of the IDNT and RENAAL trials].
    Weekers L; Krzesinski JM
    Rev Med Liege; 2001 Oct; 56(10):723-6. PubMed ID: 11765585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of type 2 diabetic nephropathy by blockade of the renin-angiotensin system: a comparison of angiotensin-converting-enzyme inhibitors and angiotensin receptor antagonists.
    Hsueh WA
    Curr Opin Pharmacol; 2002 Apr; 2(2):182-8. PubMed ID: 11950631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
    Rossing K; Christensen PK; Jensen BR; Parving HH
    Diabetes Care; 2002 Jan; 25(1):95-100. PubMed ID: 11772908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?
    Hollenberg NK; Fisher ND; Nussberger J; Moukarbel GV; Barkoudah E; Danser AH
    J Hypertens; 2011 Dec; 29(12):2454-61. PubMed ID: 22002336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy.
    Doggrell SA
    Expert Opin Pharmacother; 2002 May; 3(5):625-8. PubMed ID: 11996640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH
    Diabetes Care; 2004 Aug; 27(8):1897-903. PubMed ID: 15277414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A threat to cardiovascular risk patients. "Activated renin-angiotensin system promotes end organ damage" (interview by Waldtraud Paukstadt)].
    Schunkert H
    MMW Fortschr Med; 2004 Jun; 146(23):60. PubMed ID: 15373137
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.